Composition for down-regulating pro-inflammatory markers

A technology of composition and synergistic composition, applied in the direction of drug combination, preparation for in vivo test, medical raw material derived from angiosperm subphylum, etc., can solve problems such as danger

Inactive Publication Date: 2011-10-19
穆罕默德・马吉德
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, unrestrained production of these cytokines is more dangerous than the initial injury and it is one of the leading causes of human morbidity and mortality

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for down-regulating pro-inflammatory markers
  • Composition for down-regulating pro-inflammatory markers
  • Composition for down-regulating pro-inflammatory markers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1: Biological Activity Evaluation

[0062] Acute safety studies:

[0063] Acute oral toxicity studies were performed in mice in accordance with OECD Guideline No. 423 [Organization for Economic Co-operation and Development. OECD guidelines on chemical testing. Guideline 423, acute oral toxicity-acute toxicity class method, adopted, March 22, 1996 (Organization for Economic Cooperation and Development. OECD guidelines for testing of chemicals. Guideline 423, acute oral toxicity-acute toxic class method, adopted, March 22, 1996)] carried out. Animals were observed individually during the first 24 hours periodically, with special attention during the first 4 hours, and once daily thereafter, for a total of 14 days. A single oral (p.o.) dose of the composition administered orally to groups of female mice at 2000 mg / kg did not show any changes in the general general behavior of these test animals. Oral (p.o.) single doses of 5000 mg / kg were also evaluated. At th...

Embodiment 2

[0081] Example 2: Determination of Intracellular TNF-α, IL-1β and Nitric Oxide (NO) in vivo in Plasma from Treated Mice

[0082] BALB / c male mice aged 6-8 weeks were maintained at 22±2°C under a 12 / 12h light-dark cycle. Mice received 100, 200, 400 mg / kg of different test materials (w / v), i.e., boswellic acid components, polysaccharide components and compositions of the present invention, for 6 days, followed by oral treatment according to Brieva et al., 2001.[ Brieva A, Guerrero A, Alonso-Lebrero J Land Pivel JP. 2001. Inmunoferon, a glycoconjugate of natural origin, inhibits LPS-induced TNF-a production and inflammatory responses. International Immunopharmacology 1.1979-1987] Intravenous injection of 1 mg / kg The LPS. Six mice were used per group and experiments were performed in triplicate. Ninety minutes after LPS injection, TNF-α, IL-1β and nitric oxide production were assessed by commercial ELISA kits (R&D Systems) in mice treated from each test group. Rolipram at 30 mg...

Embodiment 3

[0084] Example 3: Adjuvant-induced developing inflammatory arthritis:

[0085] Six 12-14-week-old Wistar rats weighing 140-160 g per group were used in this study. All animals were maintained in plastic cages at 22±2°C under a 12h light / dark cycle and had free access to pelleted food and water. During the experiment, the test material was orally administered once a day. In all experiments, the control group was fed (maintained) (vehicle administered) while the other groups received the standard drug acetylsalicylic acid (ASA), administered once daily, for comparison and authenticity / authenticity of the test. The entire study was performed with permission from the Institutional AnimalEthics Committee and all animals used in the experimental work received humane care. The mean and standard error of the mean (S.E.) were calculated for each group and the results expressed as percent inhibition compared to the control group. Significance was determined statistically by applying ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a composition for down-regulating pro-inflammatory markers. The composition comprises boswellic acid fraction and polysaccharide faction obtained from Boswellia species at specific concentrations showing enhancement in their activity as compared to boswellic acid fraction and the polysaccharide fraction alone. The invention further comprises use of polysaccharide fraction individually or in combination with boswellic acid fraction for inhibition of PGE2.

Description

[0001] This application is a non-provisional application of provisional application 61 / 309481 filed March 2, 2010. technical field [0002] The present invention relates to a composition comprising a Boswellic acid fraction (fraction) obtained from the species Boswellia (Boswellia tree) and a polysaccharide fraction. The compositions are synergistic in exhibiting enhanced biological activity, in particular down-regulation (down-regulation) of pro-inflammatory markers. [0003] The present invention also relates to the use of the polysaccharide component alone or in combination (joint) with the boswellic acid component in the inhibition of PGE2. Background technique [0004] Survival is impossible without accurate regulation of the immune system. Pro-inflammatory cytokine production is a key physiological process that coordinates immune and metabolic responses during development, tissue regeneration, healing, trauma or infection and is key to protecting our body from hemorrh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/715A61K31/56A61K31/7004A61K31/7012A61P29/00A61P19/02A61P37/02A61P19/08A61P35/00A61P3/10A61P25/00A61P1/00A61P11/06A23L1/30
CPCA61K31/715A61K2300/00A61K36/324A61K31/19A61K45/06A23L33/10A23L33/105A61K31/185A61K31/7004A61K31/7012A61K31/702A61K36/00A61K36/18A23V2002/00A61K2121/00
Inventor 穆罕默德·马吉德安贾莉·潘迪萨朗·巴尼贝纳·巴特
Owner 穆罕默德・马吉德
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products